Benjamin Diamond is an Oncology physician affiliated with University of Miami. OpenAlex indexes 210 publications with 2,172 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-689-5555Provider last certified this registry record 19 Apr 2023.
Clinical trials
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Benjamin T Diamond, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year202510 payments$19,525openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20259 payments
- Janssen Scientific Affairs, LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
47.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor47.3%Acyclovir100%Part D≥15 patientsNervous system
21.9%Opioid Agonist21.9%Oxycodone Hcl53%Oxycodone-Acetaminophen47%Part D<11 patientsBlood & clotting
17.1%Factor Xa inhibitor17.1%Xarelto52%Eliquis48%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Myerburg, MD
University of Miami
Thomas Hooton, MD
University of Miami
Harry Flynn, MD
University of Miami
Alan Wein, MD
University of Miami
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”